The 10b5-1 Plan Is the Real Story at Griffon

The president of Griffon Corporation sold $1.6 million of his company's stock on the day after it reported an earnings beat, then sold more the next day, while the share price kept climbing. The headline that follows from this is usually the same one: "insider sold into strength — what does he know?"

But that headline gets the story backward. The selling is happening into strength not because Mehmel is trying to time the top, but because that is what his 10b5-1 trading plan was designed to do. The contract does the work. The timing is a feature, not a coincidence.

Here's the sequence. Griffon reported fiscal third-quarter results on August 5, beating EPS estimates by $0.17 and topping revenue expectations. The stock, which had closed the prior session at $93.58, jumped to close at $99.21 and intraday touched $103. Robert Mehmel, Griffon's president and COO, sold 14,852 shares at an average price of $105.18 on August 6. A second batch of 37,061 shares sold under the same plan at prices between $98.68 and $106.27 the next day. As of today the stock is trading at $107.22, having climbed roughly 25% in five sessions.

All of the August sales were executed under a Rule 10b5-1 trading plan. That is the SEC's mechanism for letting executives pre-arrange stock sales in advance, before they know material nonpublic information. You write the plan, specify when and how many shares you want to sell, and an independent broker carries it out on schedule. The whole point is plausible deniability. If you sell into an earnings beat, the plan was set up before you knew about the beat. That's how it is supposed to work.

The funny part — and it is not a criticism of Mehmel, who has the right to diversify — is that the market treats the calendar coincidence as information. "He sold right after earnings" reads like insider-timing even when the filing says the opposite. The 10b5-1 plan is a disclosure mechanism that turns a potentially suspicious transaction into a routine one. But it also means the plan had to be in place before the earnings were known, which implies Mehmel was already planning to sell at higher prices months ago.

That's the structural frame: the 10b5-1 plan is a forward liquidity promise to yourself. You are the buyer of your own future liquidity, and the plan is the contract that lets you collect it at whatever price the market offers when the trigger hits.

This is not an isolated event. Mehmel sold 27,359 shares on June 26 (at $95.52–$97.50) and another 4,166 shares on June 30 (at $97.76, under a 10b5-1 plan) before earnings. The CEO, Ronald Kramer, sold 100,000 shares on June 12 at $94.92 — roughly $9.5 million. Over the last 90 days, Griffon insiders collectively sold 129,389 shares worth about $12.3 million. This is a systematic reduction, not a one-off cash grab.

And yet Mehmel still holds roughly 748,839 shares after the August sales — worth about $80 million at current prices. That is the "kept $80 million" figure from the headline, and it matters because it changes the inference you should draw. If someone sells 100% of their stake into an earnings beat, that is a signal. If someone sells 5% of a $80 million position under a mechanical plan they set up months ago, that is diversification.

The bigger question is whether the earnings beat itself is worth getting excited about. Griffon's revenue was $481.4 million, which beat analyst estimates of $457.7 million. But revenue is down 21.5% year-over-year. The company lost money in the comparable quarter last year, so the swing back to $51.6 million of net income looks impressive in isolation — and it is, for a company that was bleeding — but the organic growth number of 7% masks a residential door segment that management admitted is softening. The full-year revenue guidance of $1.8 billion was reaffirmed but sits slightly below consensus estimates. The stock's 25% five-day move and 45% year-to-date gain seem to be pricing in a turnaround story that the fundamentals haven't quite confirmed yet.

So you have top executives methodically selling shares across a six-month window, using the 10b5-1 plumbing to do it legally and quietly, while the stock rips higher on a beat that reflects improved expectations more than improved trajectory. Mehmel still has $80 million at risk, which is a real stake. But he's also been systematically converting parts of it into cash at progressively better prices — $94 in early June, $97 at month-end, $105 after the jump.

The simplest model is this: the 10b5-1 plan is how executives turn a large, illiquid position into a slow stream of liquidity without triggering the kind of headline that moves the stock against them. It's not fraud. It's not a signal of imminent collapse. It's just the standard way insiders extract value while keeping enough shares to maintain the appearance of alignment.

The stock is trading at $107, near its 52-week high of $108.57, with the consensus analyst target at $115. That $8 gap looks like upside until you notice the P/E ratio sitting at 772x, a number that only makes sense if you are pricing in years of margin expansion on a shrinking revenue base. The insiders, by contrast, have a much simpler valuation model: the plan tells them when to sell, and the market tells them what price they get. No thesis required.

Anyway, the economic point is not that Mehmel is running for the exits. He isn't. He's taking a walk — a slow, mechanical, contractually pre-arranged walk — converting a fraction of his stake each time the plan fires. The question for outside investors is whether they're comfortable buying a company whose top two executives have found good reasons to be selling, even if the selling is technically routine and even if $80 million is still on the line.